129 related articles for article (PubMed ID: 11170502)
1. Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro.
Gorlewska K; Mazerska Z; Sowiński P; Konopa J
Chem Res Toxicol; 2001 Jan; 14(1):1-10. PubMed ID: 11170502
[TBL] [Abstract][Full Text] [Related]
2. The mode of action of cytotoxic and antitumor 1-nitroacridines. II. In vivo enzyme-mediated covalent binding of a 1-nitroacridine derivative, Ledakrin or Nitracrine, with dna and other macromolecules of mammalian or bacterial cells.
Pawlak JW; Pawlak K; Konopa J
Chem Biol Interact; 1983 Feb; 43(2):151-73. PubMed ID: 6402314
[TBL] [Abstract][Full Text] [Related]
3. Diminished toxicity of C-1748, 4-methyl-9-hydroxyethylamino-1-nitroacridine, compared with its demethyl analog, C-857, corresponds to its resistance to metabolism in HepG2 cells.
Wiśniewska A; Niemira M; Jagiełło K; Potęga A; Swist M; Henderson C; Skwarska A; Augustin E; Konopa J; Mazerska Z
Biochem Pharmacol; 2012 Jul; 84(1):30-42. PubMed ID: 22484277
[TBL] [Abstract][Full Text] [Related]
4. 32P-post-labeling analysis of DNA adduct formation by antitumor drug nitracrine (Ledakrin) and other nitroacridines in different biological systems.
Bartoszek A; Konopa J
Biochem Pharmacol; 1989 Apr; 38(8):1301-12. PubMed ID: 2706021
[TBL] [Abstract][Full Text] [Related]
5. Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase.
Maliepaard M; Wolfs A; Groot SE; de Mol NJ; Janssen LH
Br J Cancer; 1995 Apr; 71(4):836-9. PubMed ID: 7536024
[TBL] [Abstract][Full Text] [Related]
6. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311.
Mazerska Z; Sowiński P; Konopa J
Biochem Pharmacol; 2003 Nov; 66(9):1727-36. PubMed ID: 14563483
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
[TBL] [Abstract][Full Text] [Related]
9. Complexes of nitracrine with DNA. Stoichiometry of binding.
Szmigiero L; Gniazdowski M
Arzneimittelforschung; 1981; 31(11):1875-7. PubMed ID: 7198467
[TBL] [Abstract][Full Text] [Related]
10. 32P-post-labelling analysis of nucleobases involved in the formation of DNA adducts by antitumor 1-nitroacridines.
Bartoszek A; Dackiewicz P; Konopa J
Chem Biol Interact; 1997 Feb; 103(2):131-9. PubMed ID: 9055871
[TBL] [Abstract][Full Text] [Related]
11. Effect of substituents on the metabolism of nitracrine in rat.
Robertson IG; Bland TJ; Palmer BD
Xenobiotica; 1996 May; 26(5):559-69. PubMed ID: 8736066
[TBL] [Abstract][Full Text] [Related]
12. In vitro DNA crosslinking by Ledakrin, an antitumor derivative of 1-nitro-9-aminoacridine.
Bartoszek A; Dackiewicz P; Składanowski A; Konopa J
Chem Biol Interact; 1997 Feb; 103(2):141-51. PubMed ID: 9055872
[TBL] [Abstract][Full Text] [Related]
13. Reduction of chromium(VI) to chromium(V) by rat liver cytosolic and microsomal fractions: is DT-diaphorase involved?
Aiyar J; De Flora S; Wetterhahn KE
Carcinogenesis; 1992 Jul; 13(7):1159-66. PubMed ID: 1379126
[TBL] [Abstract][Full Text] [Related]
14. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Frei E; Sopko B; Wiessler M; Schmeiser HH
Carcinogenesis; 2002 Apr; 23(4):617-25. PubMed ID: 11960915
[TBL] [Abstract][Full Text] [Related]
15. 1H and 13C NMR characteristics of the anticancerous derivative of acridine: Ledakrin C-283 (nitracrine).
Wieczorkiewicz T; Lubas B; Siatecki Z; Kozłowski H
Acta Biochim Pol; 1983; 30(1):71-82. PubMed ID: 6868905
[TBL] [Abstract][Full Text] [Related]
16. Intercalation model for DNA-cross linking in a 1-nitro-9-aminoacridine derivative, an analog of the antitumor agent "ledakrin" (nitracrine).
Stallings WC; Glusker JP; Carrell HL; Bogucka-Ledóchowska M; Ledóchowski A; Stezowski JJ
J Biomol Struct Dyn; 1984 Dec; 2(3):511-24. PubMed ID: 6400911
[TBL] [Abstract][Full Text] [Related]
17. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
Walton MI; Workman P
Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
[TBL] [Abstract][Full Text] [Related]
18. Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate.
Driscoll JP; Kornecki K; Wolkowski JP; Chupak L; Kalgutkar AS; O'Donnell JP
Chem Res Toxicol; 2007 Oct; 20(10):1488-97. PubMed ID: 17892269
[TBL] [Abstract][Full Text] [Related]
19. The mechanism of inhibition of DNA replication in HeLa S3 cells by the antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines.
Woynarowski JM; Bartoszek A
Biochim Biophys Acta; 1985 Jun; 825(2):244-53. PubMed ID: 4005263
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of novel stable deoxyguanosine and deoxyadenosine adducts of benzo[a]pyrene-7,8-quinone from reactions at physiological pH.
Balu N; Padgett WT; Lambert GR; Swank AE; Richard AM; Nesnow S
Chem Res Toxicol; 2004 Jun; 17(6):827-38. PubMed ID: 15206904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
